171193-35-4

Basic information

• Product Name: ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate
• Synonyms: ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate;1-(Pyridin-2-yl)-1H-pyrazole-4-carboxylic acid ethyl ester;1-(2-pyridinyl)-1H-Pyrazole-4-carboxylic acid ethyl ester;Ethyl 1-(2-pyridyl)pyrazole-4-carboxylate
• CAS NO: 171193-35-4
• Molecular Formula: C11H11N3O2
• Molecular Weight: 217.22394
• Mol File: 171193-35-4.mol

Chemical Properties

• Boiling Point: 354.026 °C at 760 mmHg
• Flash Point: 167.909 °C
• Appearance: /
• Density: 1.236g/cm³
• Storage Temp.: 2-8°C
• PKA: 0.82±0.19(Predicted)
• CAS DataBase Reference: ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate(171193-35-4)
• EPA Substance Registry System: ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate(171193-35-4)

Safety Data

• Hazardous Substances Data: 171193-35-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate is used as a key intermediate for the synthesis of pharmaceutical drugs, specifically for the development of potential drug candidates that target diseases such as cancer, inflammation, and neurological disorders. Its unique structure and reactivity contribute to its value as a starting material in the design and synthesis of novel therapeutic agents.
Used in Drug Development:
Ethyl 1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate is utilized as a precursor in the creation of new drugs, facilitating the exploration of its chemical properties and reactivity to enhance the discovery of effective treatments for various medical conditions. Its role in drug development underscores its importance in advancing pharmaceutical research and innovation.

Upstream product

• 109-04-6 2-bromo-pyridine 
• 37622-90-5 4-ethoxycarbonylpyrazole 
• 372-48-5 2-fluoropyridine 
• 109-09-1 2-chloropyridine 
• 4930-98-7 pyrid-2-ylhydrazine 
• 80370-42-9 ethyl 2-formyl-3-oxopropanoate 

Downstream Products

• 28465-95-4 1-(pyridin-2-yl)-1H-pyrazol-4-amine 
• 886536-48-7 2-(4-(chloromethyl)-1H-pyrazol-1-yl)pyridine 
• 77556-50-4 2-(pyrazol-1'-yl)pyridine-4'-carboxylic acid 

Relevant articles and documents

Synthesis of Bidentate Nitrogen Ligands by Rh-Catalyzed C-H Annulation and Their Application to Pd-Catalyzed Aerobic C-H Alkenylation

A new class of bidentate ligands was prepared by a modular approach involving Rh-catalyzed C-H annulation reactions. The resulting conformationally constrained ligands enabled the Pd-catalyzed C-H alkenylation at electron-rich and sterically less hindered positions of electron-rich arenes while promoting the facile oxidation of Pd(0) intermediates by oxygen. This newly introduced ligand class is complementary to the ligands developed for Pd-catalyzed oxidative reactions and may find broad application in transition-metal-catalyzed reactions.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

NITROGEN-CONTAINING HETEROARYL DERIVATIVES

The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R1, R2, R3, R4, R5, A1, A2, and Y are as defined in the description and in

NITROGEN-CONTAINING HETEROARYL DERIVATIVES

The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R1, R2, R3, R4, R5, A1, A2, and Y are as defined in the description and in

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

Design and synthesis of a series of novel pyrazolopyridines as HIF 1-α prolyl hydroxylase inhibitors

Recently resolved X-ray crystal structure of HIF-1α prolyl hydroxylase was used to design and develop a novel series of pyrazolopyridines as potent HIF-1α prolyl hydroxylase inhibitors. The activity of these compounds was determined in a human EGLN-1 assa

A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure (I) wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

N-1 Substituted Ethyl 4-Pyrazolecarboxylates: Synthesis and Spectroscopic Investigations

The synthesis of various N-1 substituted ethyl 4-pyrazolecarboxylates via reaction of ethyl 2-formyl-3-oxopropionate (= ethoxycarbonylmalondialdehyde) with appropriately substituted hydrazines is described.Moreover, detailed nmr-spectroscopic investigations with the title compounds are presented.